A US FDA advisory committee endorsed Janssen R&D LLC’s esketamine as a potentially game-changing therapy for treatment-resistant depression but also identified some commercial challenges for the sponsor.
Members of the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee on Feb. 12 pointed to...






